Nuvectis Pharma announcse collaboration with ENGOT, GOG Foundation

Nuvectis Pharma announced a collaboration with the European Network of Gynecological Oncology Trial Groups, ENGOT, and the GOG Foundation to conduct the NXP800 Phase 1b clinical trial in ARID1A-mutated, ovarian clear cell and endometroid carcinomas in Europe and the United States. "We are honored to collaborate with the ENGOT and GOG-F on this very important clinical trial. ENGOT and GOG-F are the world’s premier gynecology oncology clinical trials consortia, representing some of the leading medical centers and having spear-headed several drug approvals in the field, including the 2 PARP inhibitors for the treatment of BRCA-mutated ovarian cancers, Olaparib and Niraparib, as well as the antibody-drug conjugate Tivdak, which is approved for cervical cancer," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Bentsur continued, "As our Phase 1a dose-escalation study in patients with advanced solid tumors is nearing completion, we have begun preparing for the start of the Phase 1b trial alongside the consortia’s world renowned experts who provide guidance into key design elements of the study protocol and access to top clinical centers." Bentsur added: "We believe that the high-quality discovery and lead optimization program at the Institute of Cancer Research, the robust preclinical proof of concept, the recent Fast Track Designation by the U.S. FDA, and now the collaboration with ENGOT and GOG-F, bode well for the future of NXP800. Clinical data from the ongoing Phase 1a trial to date suggest that the emerging clinical profile of NXP800 can provide a good balance between systemic exposure, pharmacodynamic activity and tolerability, and we look forward to the initiation of the Phase 1b trial in the next few months."